Caribou Biosciences, Inc. · NASDAQ:CRBU

Caribou Biosciences — Technical Presentation (April 2024)

12 slides from Caribou Biosciences's technical presentation, Apr 20, 2024

  1. Slide 1: CB-010 ANTLER Phase 1 trial: Results from dose escalation phase

    CB-010 ANTLER Phase 1 trial: Results from dose escalation phase Allogeneic anti-CD19 CAR-T cell with a PD-1 knockout for r/r B cell non-Hodgkin lymphoma (B-NHL) April 20, 2024 iwCAR-T meeting (Miami, FL) Loretta J. Nastoupil, MD MD Anderson Cancer Center Houston, TX

  2. Slide 2: CB-010 has a PD-1 KO designed to reduce CAR-T cell exhaustion

    CB-010 has a PD-1 KO designed to reduce CAR-T cell exhaustion CB-010 Armored with 3 genome edits PD-1 KO 1 TRAC gene knockout (KO) Anti-CD19 CAR 3 • Eliminates TCR expression, reduces GvHD risk TCR KO 2 2 Anti-CD19 CAR site-specific insertion into TRAC locus PD-L1 1 • Eliminates random integration,

  3. Slide 3: CB-010 ANTLER Phase 1 trial: dose escalation complete and enrolling 2L LBCL

    CB-010 ANTLER Phase 1 trial: Dose escalation complete and enrolling 2L LBCL patients in dose expansion Part A: 3+3 dose escalation – completed (N=16) Part B: dose expansion – enrolling • Eligibility: aggressive r/r B-NHL1 with ≥2 prior lines of • Eligibility: 2nd line LBCL2 chemoimmunotherapy or pri

  4. Slide 4: ANTLER dose escalation: baseline and disease characteristics

    ANTLER dose escalation: baseline and disease characteristics Characteristics Total (N=16) Median age, years (range) 66 (55-82) Male, n (%) 14 (88) ECOG performance status, n (%) 0 6 (38) 1 10 (62) Time since first diagnosis, years Median (range) 2.4 (0.2-16.4) Non-Hodgkin lymphoma subtype, n (%) LBC

  5. Slide 5: CB-010 has generally well-tolerated safety profile (N=16)

    CB-010 has generally well-tolerated safety profile (N=16) No DLTs at dose level 2 or dose level 3, no Grade 3+ CRS, no GvHD observed AEs of special ANTLER dose escalation (N=16) interest CRS ICANS Infections CRS ICANS1 Infections2, 3 Gr 3+ Gr 3+ Gr 3+ Any grade, N (%) 7 (44%) 4 (25%) 7 (44%) CB-010

  6. Slide 6: CB-010 ANTLER dose escalation efficacy assessment (N=16)

    CB-010 ANTLER dose escalation efficacy assessment (N=16) Overall depth and duration of response SINGLE 6-month Prior # Best CB-010 benchmark DOSE Subtype Dose Rx Resp. Pt # FL1 40M 8 CR 1 DLBCL 40M 4 CR 4 * DLBCL2 80M 1 CR 7 CR: complete response DLBCL2 80M 1 CR 8 * PR: partial response PMBCL3 40M 2

  7. Slide 7: Subgroup efficacy profile supports 2L LBCL clinical development

    Subgroup efficacy profile supports 2L LBCL clinical development r/r B-NHL r/r LBCL2 2L LBCL3 Endpoints All patients Subgroup Subgroup N, (%) (N=16) (N=10) (N=4) Overall response rate (ORR)1 15 (94%) 9 (90%) 4 (100%) Complete response (CR) rate1 11 (69%) 7 (70%) 2 (50%) ≥6-month CR rate1 7 (44%) 5 (5

  8. Slide 8: Patient #8 case report (primary refractory DLBCL patient)

    Patient #8 case report (primary refractory DLBCL patient) Age Sex Race Ethnicity Height Weight BMI BSA 66 Male Asian Not Hispanic or Latino 162.6 cm 73.2 kg 28.5 kg/m2 1.79 m2 Medical history and disease characteristics Tumor subtype DLBCL Relevant past medical history: DLBCL confirmed per • Hypergl

  9. Slide 9: Patient #8: PR to CR conversion at month 6 with ongoing CR through month 15

    Patient #8: PR to CR conversion at month 6 with ongoing CR through month 15 (80M CB-010 dose) CB-010 SINGLE PR CR DOSE Baseline Day 28 Month 3 Month 6 Month 9 Month 12 Month 15 PR at CR at D28 M6 4 EXTRANODAL LOCATIONS AT BASELINE (PET/CT) PR to CR conversion at month 6 per Lugano criteria 2 target

  10. Slide 10: Patient #8: Robust CAR-T cell expansion at day 10, ctDNA undetectable by month 3

    Patient #8: Robust CAR-T cell expansion observed at day 10 with ctDNA undetectable by month 3 ctDNA undetectable by month 3 CAR-T cell expansion observed at Day 10 in the peripheral blood 10 Poster presentation at EHA/EBMT CAR-T meeting (Feb 2024; Valencia, Spain) ANTLER CB-010 Presentation @ iwCAR-

  11. Slide 11: Patient #8: safety and cytopenia recovery

    Patient #8: safety and cytopenia recovery Lymphodepletion (LD) period No GvHD, ICANS, or infections observed with Grade 1 CRS days 4-7 Dose-limiting toxicity (DLT) evaluation Hemoglobin recovery period Neutrophil recovery Platelet recovery 11 Poster presentation at EHA/EBMT CAR-T meeting (Feb 2024;

  12. Slide 12: ANTLER CB-010 summary and next steps

    ANTLER CB-010 summary and next steps • CB-010, the first allogeneic CD19-directed CAR-T with a PD-1 knockout, demonstrated promising safety and efficacy in patients with r/r B-NHL in dose escalation (N=16) • CB-010 was generally well tolerated with adverse events consistent with anti-CD19 CAR-T cell

Caribou Biosciences — Technical Presentation (April 2024) on 6ix